L & S Advisors Inc Acquires Shares of 84,691 AstraZeneca PLC $AZNCF

L & S Advisors Inc acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the fourth quarter, Holdings Channel reports. The firm acquired 84,691 shares of the company’s stock, valued at approximately $14,863,000. AstraZeneca accounts for approximately 1.4% of L & S Advisors Inc’s holdings, making the stock its 15th largest position.

A number of other institutional investors also recently added to or reduced their stakes in AZNCF. Boston Common Asset Management LLC boosted its holdings in AstraZeneca by 5.6% during the third quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock valued at $28,992,000 after purchasing an additional 10,154 shares in the last quarter. Saranac Partners Ltd acquired a new stake in AstraZeneca during the third quarter valued at approximately $876,000. Mascoma Wealth Management LLC acquired a new stake in AstraZeneca during the fourth quarter valued at approximately $46,000. Valley Wealth Managers Inc. acquired a new stake in AstraZeneca during the fourth quarter valued at approximately $144,000. Finally, Hendley & Co. Inc. acquired a new stake in AstraZeneca during the fourth quarter valued at approximately $11,373,000. 40.87% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

OTCMKTS:AZNCF opened at $187.10 on Friday. AstraZeneca PLC has a 1 year low of $122.26 and a 1 year high of $195.00. The firm has a 50 day moving average of $187.10 and a 200-day moving average of $183.70.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.